Video

Our team behind the scenes at SXSW | Patient Stratification in Target ID, OMICS data

BenevolentAI develops AI models to help scientists better define underlying mechanisms of disease in very specific patients groups.

Looking at patient clinical and biomedical data we try to dig into molecular-level detail to redefine the disease and better endotyping for two main purposes: target identification and designing better clinical trials.

There is an abundance of patient data created e.g. electronic health records or genome sequencing. With increasing amounts of data being generated, we need AI models to help make meaningful discoveries.

Precision medicine is the future of medicine. Our belief is that by better understanding the underlying mechanisms of diseases in patients and identifying more specific and precise endotypes, we will be able to provide better medicines that are efficient in the specific patients groups they are developed for.

Watch Poojitha Ojamies, a Solutions Architect at BenevolentAI discuss how our team uses AI and machine learning to improve patient endotyping in multi-omics for target identification.  

More Posts

You Might Also Like

Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
NeurIPS 2020: Meet the BenevolentAI team
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Blog
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Blog
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
News
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020